What is the 13F Pro Quality Score for KROS?

13F Pro ranks Keros Therapeutics, Inc. (KROS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KROS's current score at https://13fpro.ai/research/KROS (free sign-up required for the full ranking).

Where does 13F Pro source KROS data?

All Keros Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Keros Therapeutics, Inc. files with the SEC under CIK 1664710. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KROS in?

Keros Therapeutics, Inc. (KROS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KROS research updated on 13F Pro?

KROS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Keros Therapeutics, Inc.(KROS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1664710 KROS stock profile & AI dashboard →

13F Pro Quality Score

57.2/100

Rank #1,058 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

16.9/100

Profitability

92.3/100

Balance Sheet

98.3/100

Earnings Quality

30.0/100

Free Cash Flow

93.1/100

Institutional Flow

8.0/100

Revenue Scale

26.6/100

Dilution Risk

15.3/100

KROS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Keros Therapeutics, Inc. (KROS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KROS at 57.2/100 on a 32-signal composite quality model, placing it at rank #1,058 of 2,879 stocks — the top half of the AI-ranked universe. KROS scores in the top quartile across balance sheet strength (98.3), free cash flow (93.1), profitability (92.3). Areas of concern include institutional flow (8.0) and revenue growth (16.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Keros Therapeutics, Inc. reports quarterly revenue of $32.0K, net income of $-23.7M, free cash flow of $-3.6M. Top institutional holders of KROS by reported 13-F value include BlackRock,, Nantahala Capital Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. KROS trades on the Nasdaq exchange and files with the SEC under CIK 1664710. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KROS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Keros Therapeutics, Inc. directly from SEC EDGAR. Keros Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 74 since 2022, currently 57.2 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Keros Therapeutics, Inc.

Quirks, history, and lore behind KROS — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on diseases with no good treatments.
2
The Numbers
A pre-revenue biotech with a market cap in the hundreds of millions — the kind of company where the cash runway matters more than the income statement.
3
The History
Founded around 2016, it went public in 2020 and has been quietly building a pipeline targeting rare muscle and blood disorders ever since.
4
The Secret
Its entire scientific bet rides on the TGF-beta superfamily signaling pathway — a biological control system that governs muscle growth, bone formation, and red blood cell production.
5
The Lore
Its lead programs take aim at brutal conditions like facioscapulohumeral muscular dystrophy and myelodysplastic syndromes — diseases that pharma giants have largely ignored.
6
The Giveaway
The company's name is a nod to Keros — and its ticker KROS is almost as easy a clue as the fact that it's a rare-disease biotech hunting inside the TGF-beta pathway.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$32.0K

Net Income

Q1 2026

$-23.7M

Free Cash Flow

Q1 2026

$-3.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$243.9MFY 2025

FY22 $0.00FY23 $151.0KFY24 $0.00FY25 $243.9M

Net Income

+146.4% YoY

$87.0MFY 2025

FY22 $-104.7MFY23 $-153.0MFY24 $-187.4MFY25 $87.0M

Operating Income

+132.0% YoY

$67.6MFY 2025

FY22 $-114.8MFY23 $-169.9MFY24 $-210.8MFY25 $67.6M

EPS (Diluted)

+146.0% YoY

$2.30FY 2025

FY22 $-4.15FY23 $-5.20FY24 $-5.00FY25 $2.30

Total Assets

-45.1% YoY

$338.0MFY 2025

FY22 $306.8MFY23 $370.0MFY24 $615.9MFY25 $338.0M

Op. Cash Flow

+166.8% YoY

$107.5MFY 2025

FY22 $-70.1MFY23 $-124.5MFY24 $-160.9MFY25 $107.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$243.9M	$0.00 -100.0%	$151.0K	$0.00 -100.0%	$20.1M +101.0%	$10.0M
Net Income	$87.0M +146.4%	$-187.4M -22.5%	$-153.0M -46.2%	$-104.7M -78.2%	$-58.7M -376.2%	$-12.3M
Operating Income	$67.6M +132.0%	$-210.8M -24.1%	$-169.9M -48.0%	$-114.8M -103.6%	$-56.4M -433.7%	$-10.6M
EPS (Diluted)	$2.30 +146.0%	$-5.00 +3.8%	$-5.20 -25.3%	$-4.15 -64.7%	$-2.52	—
Total Assets	$338.0M -45.1%	$615.9M +66.4%	$370.0M +20.6%	$306.8M +20.2%	$255.3M +2230.0%	$11.0M
Operating Cash Flow	$107.5M +166.8%	$-160.9M -29.2%	$-124.5M -77.7%	$-70.1M -12.7%	$-62.1M -288.5%	$-16.0M

AI Insight: KROS Ratio Trends

Keros collapsed from profitability in Q1 2025 to persistent losses, with ROIC swinging from +83.4% to -36.2% in one year.

• Q1 2025 showed OpMargin +72.0%, NPM +70.3%, ROIC +83.4%—a sharp profitable quarter amid otherwise negative returns.

• Q2 2025 onward, returns collapsed: NPM fell to -169.0%, ROE to -17.4%, ROIC to -22.5%, signaling operational deterioration.

• TTM ROIC at -38.6% matches Q4 2025 level, indicating sustained negative returns over trailing twelve months.

⚠ Q1 2025 profitability spike was not sustained; investigate whether it reflected timing, one-off revenue, or execution breakdown.

⚠ Q3 2025 OpMargin crashed to -108.9% with NPM at -51.5%—steepest loss quarter; root cause and recovery trajectory unclear.

Get alerted when KROS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Keros Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KROS

BlackRock, Inc.
$26.6M2,411,793 sh
Nantahala Capital Management, LLC
$15.0M1,360,419 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.2M831,421 sh
ORBIMED ADVISORS LLC
$8.4M759,155 sh
Qube Research & Technologies Ltd
$8.0M724,926 sh
JACOBS LEVY EQUITY MANAGEMENT, INC
$7.8M706,071 sh
FEDERATED HERMES, INC.
$7.6M689,229 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$7.5M682,043 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.5M681,460 sh
Madison Avenue Partners, LP
$6.9M626,583 sh

Fund	Value	Shares
BlackRock, Inc.	$26.6M	2,411,793
Nantahala Capital Management, LLC	$15.0M	1,360,419
VANGUARD CAPITAL MANAGEMENT LLC	$9.2M	831,421
ORBIMED ADVISORS LLC	$8.4M	759,155
Qube Research & Technologies Ltd	$8.0M	724,926
JACOBS LEVY EQUITY MANAGEMENT, INC	$7.8M	706,071
FEDERATED HERMES, INC.	$7.6M	689,229
VANGUARD PORTFOLIO MANAGEMENT LLC	$7.5M	682,043
GEODE CAPITAL MANAGEMENT, LLC	$7.5M	681,460
Madison Avenue Partners, LP	$6.9M	626,583

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KROS on your watchlist

Track score changes the day Keros Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KROS a good stock to buy?

13F Pro's AI-powered analysis of Keros Therapeutics, Inc. (KROS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KROS are available on the KROS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KROS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KROS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Keros Therapeutics, Inc.'s investment landscape.